stoxline Quote Chart Rank Option Currency Glossary
Oncorus, Inc. (ONCR)
0.021  0 (0%)    12-01 15:42
Open: 0.021
High: 0.038
Volume: 27,106
Pre. Close: 0.021
Low: 0.021
Market Cap: 1(M)
Technical analysis
2023-12-01 4:21:50 PM
Short term     
Mid term     
Targets 6-month :  0.04 1-year :  0.05
Resists First :  0.03 Second :  0.04
Pivot price 0.02
Supports First :  0.02 Second :  0.01
MAs MA(5) :  0.02 MA(20) :  0.02
MA(100) :  0.02 MA(250) :  0.18
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 46.7
52-week High :  0.52 Low :  0.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ONCR ] has closed above bottom band by 43.3%. Bollinger Bands are 56.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.04 - 0.04 0.04 - 0.04
Low: 0.02 - 0.02 0.02 - 0.02
Close: 0.02 - 0.02 0.02 - 0.02
Company Description

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 13 Sep 2023
North American Morning Briefing: Stock Futures -2- - Morningstar

Mon, 26 Jun 2023
Hilco Streambank Seeks Offers to Acquire Patent Portfolio of ... - PR Newswire

Wed, 21 Jun 2023
U.S. stocks lower at close of trade; Dow Jones Industrial Average ... -

Mon, 12 Jun 2023
Oncorus liquidates a week after shedding workforce - FierceBiotech

Mon, 12 Jun 2023
Why Is Oncorus (ONCR) Stock Down 27% Today? - InvestorPlace

Mon, 05 Jun 2023
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 26 (M)
Shares Float 24 (M)
Held by Insiders 13.4 (%)
Held by Institutions 41.7 (%)
Shares Short 448 (K)
Shares Short P.Month 164 (K)
Stock Financials
EPS -3.49
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.19
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -32.3 %
Return on Equity (ttm) -124.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.68
Qtrly Earnings Growth 0 %
Operating Cash Flow -56 (M)
Levered Free Cash Flow -54 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0.01
Price to Sales 0
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android